Cboe BZX · HELX
Franklin Genomic Advancements ETF financials
$44.40+0.23%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 | FY15 Dec 31 | FY14 Dec 31 | FY13 Dec 31 | FY12 Dec 31 | FY11 Dec 31 | FY10 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $751.9M | $739.8M | $581.4M | $487.6M | $695.8M | $1.11B | $876.6M | $846.1M | $702.0M | $774.5M |
| Gross profit | $137.8M | $121.7M | $62.2M | $46.5M | $111.2M | $344.0M | $260.7M | $227.1M | $156.2M | $168.9M |
| Gross margin | 18.3% | 16.4% | 10.7% | 9.5% | 16.0% | 31.1% | 29.7% | 26.8% | 22.3% | 21.8% |
| Operating income | $68.0M | $51.4M | -$1.1M | -$64.5M | -$307.5M | $251.5M | $178.4M | -$44.5M | $63.0M | $42.0M |
| Net income | $57.3M | $28.3M | $30.1M | -$81.4M | -$377.0M | $195.0M | $109.9M | -$46.3M | $128.3M | -$127.1M |
| Net margin | 7.6% | 3.8% | 5.2% | −16.7% | −54.2% | 17.6% | 12.5% | −5.5% | 18.3% | −16.4% |
| Diluted EPS | $0.38 | $0.19 | $0.20 | $-0.73 | $-3.58 | $1.85 | $1.04 | $-0.44 | $1.23 | $-1.22 |
| EBITDA | $180.7M | $161.9M | $107.7M | $94.8M | $174.4M | $360.9M | $277.0M | $229.8M | $160.8M | $144.7M |
| Operating cash flow | $169.7M | $196.7M | $51.6M | $38.7M | $110.8M | $359.5M | $74.4M | $452.5M | $567.2M | $331.5M |
| Free cash flow | $28.8M | $59.7M | -$179.5M | -$147.8M | -$209.5M | $22.6M | -$250.1M | $129.5M | $467.0M | $209.2M |
| Diluted shares | 149.6M | 146.8M | 145.3M | 111.6M | 105.4M | 105.0M | 105.2M | 104.4M | 105.0M | 103.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $208.4M | $279.5M | $266.6M | $356.6M | $494.2M | $476.5M |
| Short-term investments | — | — | — | — | — | — |
| Total debt | $405.9M | $440.3M | $495.6M | $626.0M | $749.3M | $551.4M |
| Total assets | $2.60B | $2.35B | $2.36B | $2.25B | $2.40B | $2.70B |
| Total liabilities | $893.7M | $730.0M | $795.4M | $965.1M | $1.12B | $1.05B |
| Shareholders' equity | $1.70B | $1.62B | $1.57B | $1.28B | $1.28B | $1.65B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology